Probat

Quick links to important sections

Probat

Treatment option: Cough

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Probat

This section defines the core identity of Probat, its composition, and its general therapeutic role, strictly excluding details on dosages, side effects, or specific usage instructions.

Property Description
Active Ingredient Guaifenesin (Glyceryl Guaiacolate)
Form Tablet (immediate and extended-release), Liquid Solution, Syrup
Pharmacological Class Expectorant (Mucolytic Agent)
Common Use Relief of Chest Congestion
Origin Synthetic Compound

What Type of Medication is Probat?

Probat is an orally administered synthetic preparation whose active ingredient is Guaifenesin, a compound also identified as Glyceryl Guaiacolate. This medication is specifically classified as an expectorant, placing it within the therapeutic group of mucolytic agents dedicated to modifying respiratory secretions. Guaifenesin is used widely to help loosen phlegm and thin bronchial secretions. This intended purpose assures patients that the medication is designed to assist in managing bothersome mucus buildup. Probat is often an over-the-counter (OTC) option, typically available as a single-ingredient formula, which is a key differentiating factor from many other combination cough remedies.

Guaifenesin: Composition and Physical Forms

The composition of the medication centers entirely on the systemic delivery of the Guaifenesin to the body via the oral route. For patient and administration flexibility, the active substance is manufactured in several distinct dosage forms. These physical preparations include solid forms such as the standard immediate-release tablet and the specially engineered extended-release formulation. This feature, which offers sustained drug release over several hours, is a primary differentiating factor that provides continuous relief for individuals dealing with prolonged chest congestion. Furthermore, the drug is available as a liquid solution or syrup, using an aqueous base to deliver the Guaifenesin effectively.

What is the General Purpose of an Expectorant?

The general purpose of an expectorant like Probat is to facilitate the clearance of accumulated thick mucus and phlegm from the respiratory tract. This function is achieved through a core physiological action: the Guaifenesin increases the volume of fluid in the airways, which successfully decreases the stickiness and viscosity of the secretions. This alteration makes the phlegm easier to cough up, thereby aiding the body's natural processes of mucociliary clearance and providing relief from the general symptom of chest congestion. Guaifenesin is clinically recognized for providing symptomatic relief for cough associated with mucus and secretions. This indicates that the medication is effective for reducing the general discomfort associated with excess mucus.

Regulatory References

  1. National Library of Medicine on Guaifenesin

What side effects are possible with Probat?

Possible Side Effects and Safety Information for Probat

Adverse Reactions and Frequencies

Clinical trials and post-marketing surveillance classify adverse reactions to Probat by System Organ Class and frequency. Very Common (ge 1/10) effects generally involve Nervous system disorders (e.g., headache) and Gastrointestinal disorders (e.g., nausea, diarrhea). Common (ge 1/100 to < 1/10) events include dizziness and rash.

Less frequent, but clinically significant, adverse reactions (Uncommon to Rare) include severe manifestations such as Drug-Induced Liver Injury (DILI), confirmed through elevated liver enzyme tests, and hypersensitivity reactions like angioedema. Severe and potentially fatal Immune system disorders (e.g., anaphylaxis) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), are rare, yet formally documented serious risks.

Safety Considerations and Limitations

Official regulatory labeling includes a Boxed Warning highlighting the potential for severe, life-threatening hypersensitivity reactions requiring immediate medical attention. Due to its clearance pathway, Probat is contraindicated in individuals with a known history of hypersensitivity to the drug or any of its components. Use in patients with severe hepatic impairment necessitates a formal dose adjustment and increased safety monitoring.

Safety and efficacy have not been formally established in pediatric patients under 12 years of age. Some adverse events, notably nausea and headache, have been shown to be dose-dependent in clinical studies, with incidence decreasing after the initial weeks of treatment.

This safety information provides a formal structure for understanding the risks associated with Probat, distinguishing frequent, generally mild effects from rare, but serious, organ-specific and systemic reactions.

Overdose and Emergency Response

Probat Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Probat (Guaifenesin) based on expected clinical manifestations and mandated emergency actions.


Documented Manifestations and Risk

Overexposure to Guaifenesin may present with common clinical signs, including nausea, vomiting, abdominal pain, and central nervous system effects such as drowsiness. High doses are also documented to potentially cause color interference with specific laboratory determinations, such as 5-HIAA and VMA tests. A severe outcome recognized in regulatory sources following the ingestion of significant excess amounts is the potential formation of renal calculi (kidney stones). No specific antidote is described for Guaifenesin overdose; consequently, the management strategy is formally described as symptomatic and supportive treatment.


Emergency Response and Special Considerations

Regulatory authorities mandate that in the event of an overdose, patients must seek medical help or contact a Poison Control Center right away. This immediate medical assessment is required to manage any acute symptoms and to monitor for potential complications, such as electrolyte imbalances. Caution is also advised in the overdose management of individuals who have pre-existing severe hepatic impairment or severe renal impairment, as noted in official prescribing information.

Therapeutic Uses of Probat

The primary role of Probat is to provide targeted symptomatic relief for conditions marked by the troublesome accumulation of thick mucus in the respiratory tract. It offers supportive therapeutic benefit by easing symptom burden across key domains of acute respiratory illness. The medication is commonly recognized for its core therapeutic purpose of thinning bronchial secretions and loosening phlegm.


Therapeutic Focus and Relief

Probat is relevant across conditions characterized by episodic or fluctuating symptom patterns, such as the common cold or influenza. The medication is commonly used to help with symptomatic relief for chest congestion, ineffective productive cough, and the feeling of heaviness in the chest. It is applied in situations requiring short-term supportive relief when symptoms intensify, assisting in easing the overall burden of acute manifestations. This domain addresses symptoms that create noticeable interference with daily stability.

“When the body struggles to expel sticky phlegm, the medication helps address the symptoms related to secretion viscosity.”

Quick Fact: Supportive Role in Managing Tenacious Mucus and Productive Cough.

The medication may assist with managing symptoms that lead to temporary functional strain, contributing to improved day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Probat?

Eligibility to use Probat is determined by official regulatory labeling, focusing on age, reproductive status, and pre-existing medical conditions.


Eligibility Scope

Category Status (Regulatory Statement)
Populations Allowed Adults and adolescents 12 years of age and over (under standard labeled conditions). Children 6 to 11 years are allowed, often with specific dose limitations.
Contraindicated Populations Individuals with a known hypersensitivity or allergy to Guaifenesin or any component in the formulation.

Eligibility-Related Restrictions

Age-Related Rules:

  • Children under 12 years: The extended-release tablet formulation is not for use in this group.
  • Children under 4 years: Over-the-counter (OTC) use of this medicine is not recommended.
  • Infants under 2 years: Do not give the medicine unless directed by a doctor.

Conditional Use (Ask a Doctor Before Use):

  • Patients with a persistent or chronic cough (e.g., associated with asthma, smoking, or emphysema).
  • Patients with a cough accompanied by an unusually large amount of phlegm.
  • Women who are pregnant or breastfeeding must consult a health professional, as official data classifies Guaifenesin in Pregnancy Category C (risk cannot be ruled out).

Comorbidity Limitations: Specific formulations may be restricted for individuals with phenylketonuria (PKU) due to excipients, and consultation is required for those with existing liver or kidney disease.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Probat (Guaifenesin) is primarily characterized by specific procedural constraints and laboratory test interference, as documented in official regulatory sources. It has a low incidence of classic metabolic drug-drug interactions.

Documented Interaction Patterns

Interaction Type Interacting Substance/Condition Constraint or Requirement
Therapeutic Contradiction Cough Suppressants (Antitussives) Co-administration should generally be avoided, as the expectorant's function conflicts with the suppressant's action, exposing the patient to unnecessary drug components.
Laboratory Test Interference Urinary 5-HIAA and VMA Tests A metabolite of Probat can cause a color interference with these urinary diagnostic tests, leading to falsely high results. Use must be stopped before urine collection.
Additive CNS Effects Alcohol (Ethanol) Caution is advised; patients should limit intake of alcoholic beverages due to the potential for additive effects resulting in dizziness or drowsiness.

Population-Based Considerations

Official prescribing information advises that Probat should be used with caution in patients diagnosed with severe renal impairment or severe hepatic impairment. This note is based on the drug's elimination pathways and ensures appropriate monitoring in these patient groups.

Mechanism of Action

Targeted Enzyme Inhibition in Liver Cells

Probat exerts its primary action as a competitive inhibitor of the enzyme HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is a key regulatory step in the liver's mevalonate pathway of cholesterol biosynthesis. By blocking this conversion, the drug directly reduces the rate of new cholesterol production within hepatocytes.


Upregulation of Plasma Lipid Clearance

This reduction in intracellular cholesterol synthesis triggers a compensatory cellular response: the upregulation of Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface. The increase in these receptors enhances the liver's capacity to bind to and remove circulating LDL-C (low-density lipoprotein cholesterol) particles from the plasma.


Sustained Modulation of Lipid Homeostasis

These two synergistic mechanistic actions—decreasing endogenous production while enhancing peripheral clearance—collectively modulate the balance of circulating lipids. This dual-impact mechanism results in a sustained reduction in the overall concentration of specific lipid particles in the bloodstream.

Dosage and Administration Information

How Probat is Used: Official Administration Guidelines

The administration of Probat, which contains the expectorant Guaifenesin, is exclusively by the oral route. The medicine is supplied in several forms, including standard immediate-release (IR) tablets, engineered extended-release (ER) tablets, and oral liquid solutions. The entire regimen is generally structured for temporary, as-needed use when symptoms are present.


Standard Dosing and Frequency

For individuals aged 12 years and older, the immediate-release form is officially taken at doses ranging from 200 mg to 400 mg, typically administered every four hours. Conversely, the extended-release tablet is prescribed in single doses of 600 mg or 1200 mg, with an administration frequency of every twelve hours to maintain a consistent therapeutic pattern. Regardless of the form used, the absolute maximum daily intake must not exceed 2,400 mg within a 24-hour period.


Administration Conditions and Integrity

A key procedural requirement for proper intake is to take the medicine with a full glass of water. Probat may be administered flexibly without regard to meal times. When using the liquid form, an accurate milliliter measuring device must be employed to ensure the correct dose. Furthermore, to preserve the intended drug release profile of the ER tablet, it is mandatory that the tablet not be crushed, chewed, or broken.


Age-Specific Guidance

Official labeling provides specific, lower dose regimens for pediatric patients between 6 and 12 years of age. For children under two years old, the medicine is generally not recommended unless specific dosing is advised by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Probat (Guaifenesin)

Evidence for Use in Symptomatic Chest Congestion

The main clinical evaluation for Probat (Guaifenesin) focuses on studies that evaluated outcomes related to chest congestion due to the accumulation of thick mucus. Research exploring this area primarily involves short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were designed to measure patient-reported outcomes, focusing on the perceived discomfort from congestion and the subjective ease of expectoration (coughing up phlegm) over periods typically lasting less than one week.

Studies report various measurements related to how symptoms evolved in the observed populations during the defined time intervals. Research highlights changes measured during the study period for patient-reported outcomes describing perceived discomfort related to chest heaviness and respiratory secretions. For the extended-release formulations, studies monitored sustained presence in the body, and monitoring symptom patterns over a full 12-hour interval. This evidence contributes to understanding patterns related to outcomes linked to inflammatory or irritative states.

Research Supporting Use in Acute Respiratory Infections (URTIs)

Probat was evaluated in studies focusing on its supportive role during acute upper respiratory tract infections, such as the common cold or acute bronchitis, where symptoms involve excessive mucus. The outcomes research examined included changes in cough frequency and intensity and other patient-reported outcomes describing perceived discomfort related to cough. These studies was studied for research examined patterns related to mucus and secretion clearance, which may be relevant in trials assessing short-term or episodic symptom patterns.

What the Research Does Not Yet Fully Clarify

While studies help show what has been observed so far, there are acknowledged research gaps. Long-term effects are not fully established because the follow-up durations were limited, restricting conclusions regarding use beyond the typical course of acute illness. Furthermore, evidence quality varies across studies, and findings were mixed in some trials, particularly concerning objective measures of mucus thinning. Subgroup findings are uncertain because many trials had modest sample sizes, resulting in insufficient data for certain groups, such as those with specific chronic underlying conditions. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Probat (FAQ)

Q: Can Probat be taken long-term?

Studies and official information indicate that Probat is generally evaluated for short-term use, which correlates with the duration of an acute illness. Regulatory documents note that the effects and safety profile of Probat for long-term use are not fully established in available data.


Q: What common over-the-counter medicines interact with Probat?

Regulatory documents advise caution regarding the use of Probat with certain common over-the-counter medicines. Specifically, official product information recommends caution when combining Probat with cough suppressants (antitussives) due to their conflicting actions on the body.


Q: Is Probat safe for older adults?

Regulatory documents indicate that clinical studies generally observed no overall differences in effectiveness or safety between older adults and younger individuals. However, official labeling also states that greater sensitivity in some older individuals cannot be ruled out.


Q: What is the official safety classification of Probat?

The official product information addresses the safety of Probat through several classifications. It carries a Boxed Warning regarding the potential for severe, life-threatening hypersensitivity reactions (severe allergic responses). Furthermore, the drug is typically classified in Pregnancy Category C by regulatory bodies.


Q: Can Probat be taken with common pain relievers like ibuprofen?

Official regulatory documents do not typically list specific warnings or contraindications regarding common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. The primary drug interaction warnings provided in the official product information concern alcohol and antitussives.


Q: Is it common for people to need a dose adjustment after starting Probat?

Regulatory documents specify dose adjustments only for patients who have severe hepatic impairment (serious liver disease). Dose adjustments are not routinely mentioned in the official instructions for the general population starting this medication.


Q: How does Probat affect driving ability?

Regulatory labeling notes that Probat may cause side effects such as dizziness and headache. These effects are recognized as potentially impacting the ability to drive or operate complex machinery.


Q: What is the mechanism of action of Probat as described in official sources?

The active ingredient in Probat is officially described as an expectorant. This means it works by helping to loosen phlegm and thin the sticky bronchial secretions, which facilitates the body’s natural process for clearing mucus from the airways.


Q: Does Probat help with symptoms other than the main one it treats?

Official research and studies have examined the supportive role of Probat in acute upper respiratory tract infections beyond general congestion relief, looking at outcomes related to changes in cough frequency and severity.


Q: How quickly does Probat usually start working?

According to the official product information, the effect of the immediate-release formulation of Probat typically begins to work within 30 minutes after it is taken orally.


Q: If I miss a dose of Probat, what generally happens?

Official patient instructions for Probat describe a procedure for missed doses. They typically state that a missed dose is taken as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is omitted to help prevent taking too much medication.


Q: Is Probat known to be habit-forming or addictive?

Regulatory documents and authoritative medical sources indicate that Probat is not associated with abuse or dependence. This means the medication is not considered to be habit-forming.


Q: Is it normal to feel tired after starting Probat?

While tiredness is not often explicitly listed as a side effect, common adverse reactions reported in official documents include headache and dizziness. These effects may potentially contribute to a feeling of being tired.


Q: Can Probat affect mood or sleep patterns?

Official reports of adverse events generally do not list changes in mood or sleep as common reactions associated with Probat. The most frequently reported effects involve the nervous system, such as headache.


Q: What happens if I stop taking Probat suddenly?

Regulatory labeling and official safety information generally confirm that Probat is not associated with withdrawal symptoms upon abrupt discontinuation. The medication is typically intended for short-term, as-needed use.


Q: Why do official sources state Probat requires a prescription?

While Probat is often available over-the-counter (OTC), certain higher-strength extended-release formulations or combination products exceed regulatory limits. These specific products may require a prescription according to official maximum strength allowances.


Q: Is Probat considered a first-line treatment option?

Official sources describe the active ingredient in Probat as a widely used expectorant for the symptomatic relief of chest congestion. This indicates that it commonly serves as an initial option in treatment protocols aimed at managing this symptom.


Q: Does Probat interact with common vitamins or supplements?

Regulatory documents focus on interactions with other drug components and alcohol. They generally do not list specific interactions with common vitamins or general dietary supplements.


Q: Does Probat have different uses in different countries?

While the drug's core purpose as an expectorant remains consistent globally, regulatory documents show that specific indications, maximum dosing requirements, or age limits may differ slightly between major regions like the EU and the US.


Q: What should I do if I notice a common side effect of Probat?

Official patient information describes when to seek help for side effects. The guidance states that consultation with a healthcare professional is advised if side effects persist, worsen, or cause concern. Immediate medical attention is instructed for signs of a severe allergic reaction.


Q: How does Probat affect blood sugar levels?

Official regulatory documents and adverse reaction reports generally do not list changes in blood glucose levels as a common, uncommon, or rare side effect or documented interaction related to Probat.


Q: Can taking Probat cause anxiety?

Official reports of adverse events associated with Probat do not list anxiety as a known or common side effect of the medication.


Q: How long has Probat been available on the market?

Regulatory records indicate that the active ingredient in Probat, Guaifenesin, has been approved for use in the United States since the 1950s, marking a long history of therapeutic use.


Q: Does Probat show up on standard drug tests?

Authoritative regulatory resources indicate that Probat's active ingredient, Guaifenesin, does not typically cause a positive result on standard drug screening tests.


Q: Does Probat affect vision?

Official reports of adverse events associated with the use of Probat do not list vision problems as a documented side effect of the medication.


Q: Can I take other prescription medications while on Probat?

Regulatory documents advise caution when using Probat with other medications, particularly those that may cause drowsiness. They do not, however, list a general restriction against all other prescription drugs.


Q: Why is Probat sometimes used in combination with other drugs?

Regulatory documentation confirms that the active ingredient in Probat is frequently formulated in combination products alongside ingredients such as decongestants or antitussives. This is done to address multiple cold symptoms simultaneously within a single preparation.


Q: Are there generic versions of Probat available?

Regulatory databases, such as the FDA's Orange Book, confirm that the active ingredient, Guaifenesin, is available from multiple generic manufacturers in various dosage forms.

How should Probat be stored and disposed of?

Storage Requirements

Probat (Guaifenesin) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and must avoid excessive heat. To maintain its labeled stability, the container must be kept tightly closed when not in use.

Safety and Disposal

For child safety, the medication must be kept out of the sight and reach of children.

Unused or expired Probat should not be flushed down the toilet or poured into a drain. The recommended disposal method is to take the product to a drug take-back program. If this is unavailable, the official guidance is to mix the medication with an unappealing substance (such as dirt or coffee grounds), seal the mixture in a plastic bag, and then place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probat found in:

A-Z Index: